ASX Linkedin Twitter               

 

Clinical Advisory Board

Keith Flaherty, MD

Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School

Dr. Flaherty is Chair of the Clinical Advisory Board and previously served on Viralytics’ Scientific Advisory Board. He is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center and he is an Professor of Medicine at Harvard Medical School. His research and clinical focus is on melanoma with a particular expertise in targeted therapies. Dr. Flaherty has been the Principal Investigator for numerous human clinical trials with a focus on novel, targeted drugs for metastatic melanoma patients. In these trials, he focused on the development of response and predictive biomarkers to define the mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population.

Michael Boyer, MD, PhD

Clinical Professor at the Sydney Medical School, the University of Sydney and Chief Clinical Officer Chris O’Brien Lifehouse

Dr Boyer is a medical oncologist with clinical interests in the management of thoracic malignancies and head and neck cancers. His major research focus is on the clinical development of new agents for the management of lung cancer and mesothelioma.  The author of over 145 publications and a frequent presenter at national and international conferences, Dr Boyer is actively involved in the lung cancer community. He chaired the scientific advisory committee of the Australasian Lung Cancer Trials Group between 2004 and 2011, and was the conference Co-President for the 15th World Conference on Lung Cancer held in Sydney in 2013. He is currently a member of the Board of Directors of the International Association for the Study of Lung Cancer.

Joel R Hecht, MD

Professor of Clinical Medicine at the David Geffen School of Medicine at the UCLA School of Medicine

Dr Hecht holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is also the Director of the UCLA Gastrointestinal Oncology Program. He is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. Dr Hecht has led and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and major phase II and phase III trials with novel agents.

Kurt Schalper, MD, PhD

Assistant Professor of Pathology at the Yale School of Medicine and Director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center

Dr Schalper is focused on leveraging advances in targeted therapy and immunotherapy to develop new treatments that will improve outcomes for cancer patients.  He is a member of a Stand Up To Cancer – American Cancer Society Dream Team formed to discover novel, targeted immunological approaches to treating KRAS-mutant lung cancers. At Yale, he also helped to develop a new objective, quantitative, and reproducible assay for measuring anti-tumour immune activity in non-small cell lung cancer tumours – an advance that could lead to novel immunostimulatory therapies.

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).